Form 8-K

8-K — Indivior Pharmaceuticals, Inc.

Accession: 0001193125-26-436953

Filed: 2026-10-29

Period: 2026-10-29

CIK: 0001625297

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — d169609d8k.htm (Primary)

EX-99.1 (d169609dex991.htm)

GRAPHIC (g169609g98n48.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d169609d8k.htm · Sequence: 1

8-K

false 0001625297 0001625297 2026-10-29 2026-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2026

INDIVIOR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-37835

41-2520873

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

10710 Midlothian Turnpike, Suite 125

North Chesterfield, VA

23235

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: 804-379-1090

n/a

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☒

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

common stock, $0.001 par value per share

INDV

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On October 29, 2026, Indivior Pharmaceuticals, Inc. (“Indivior” or the “Company”) issued a press release reporting its financial results for the period ended September 30, 2026. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release dated October 29, 2026.

104

Cover page interactive data file (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Indivior Pharmaceuticals, Inc.

Date: October 29, 2026

By:

/s/ Ryan Preblick

Name: Ryan Preblick

Title: Chief Financial Officer

EX-99.1

Filename: d169609dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Indivior Reports Third Quarter 2026 Financial Results

• Q3’26 Total Net Revenue of $356 Million, Up 13% YoY

• Record Quarterly Total SUBLOCADE® Net Revenue of $267 Million in

Q3’26, Up 22% YoY

• Record Quarterly Net Income of $137 Million and Record

Non-GAAP Net Income of $161 Million in Q3’26

• Record Quarterly Adjusted

EBITDA of $211 Million in Q3’26, Up 76% YoY

• Net Income Margin of 39%, up 2,500 basis points YoY, Adjusted EBITDA

Margin of 59%, Up 2,100 Basis Points YoY

• On Track to Close Merger with Supernus on November 2nd

Richmond, VA, October 29, 2026 – Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the

third quarter ended September 30, 2026.

“In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA,

reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda,” said Joe Ciaffoni, Chief Executive Officer. “Upon the imminent closing of our merger with Supernus, we will have successfully completed

all three phases of the Indivior Action Agenda. I want to thank the Indivior team for their commitment and hard work that generated these results and made the transaction with Supernus possible. I am confident in Supernus’ future and its

ability to build on this strong foundation for people living with central nervous system diseases and to create long-term value for shareholders.”

“We achieved record financial performance in the third quarter, including SUBLOCADE net revenue growth of 22% year-over-year and adjusted EBITDA margin

of 59%, up 2100 basis points year-over-year,” said Ryan Preblick, Chief Financial Officer. “Our strong results and the execution of our Indivior Action Agenda puts us on track to achieve our previously communicated 2026 financial

guidance, excluding the impact of our pending acquisition. Strong cash generation brought cash and investments to $332 million at quarter end, adding to the financial strength we will bring to our merger with Supernus.”

Q3 2026 Business Highlights:

•

As of September 30, 2026, over 583,000 patients in the U.S. have been prescribed SUBLOCADE since launch.

•

Grew total SUBLOCADE net revenue 22% year-over-year to $267 million. U.S. SUBLOCADE net revenue increased

24% year-over-year to $252 million versus the prior year, primarily driven by 17% dispense unit volume growth. Net revenue also benefited from more favorable price/mix and

gross-to-net adjustments.

•

In August 2026, Indivior and Supernus Pharmaceuticals, Inc. (“Supernus”) announced a definitive

agreement to combine in an all-stock merger of equals transaction to create a leading, diversified, scaled, CNS-focused biopharmaceutical company.

•

In September 2026, Indivior announced that its Board of Directors declared a special cash dividend contingent

upon closing of the pending merger transaction with Supernus.

•

In October 2026, Indivior shareholders approved the proposed merger with Supernus. The merger is expected to

close on November 2, 2026, at which time the combined company will operate as Supernus, Inc. and will trade on the Nasdaq Global Select Market under the ticker symbol “SUPN” beginning November 3, 2026.

Full-Year 2026 Financial Guidance:

Prior to the

closing of the merger, Indivior is on track to achieve its previously communicated full year 2026 guidance as a standalone organization. That guidance assumed no material change in exchange rates for key currencies compared with 2025 average rates,

notably USD/GBP and USD/EUR. Assuming the merger is completed November 2, 2026, we will operate as a combined company and the guidance will no longer apply.

FY 2026 Guidance

Net Revenue

1,295 million to $1,365 million

Total SUBLOCADE Net Revenue

1,010 million to $1,050 million

Non-GAAP Operating Expenses*

430 million to $450 million

Adjusted EBITDA*

700 million to $740 million

We did not provide the forward-looking U.S. GAAP equivalents for certain forward-looking non-U.S. GAAP metrics as a result of the uncertainty and potential variability of reconciling items. Instead, the Company has relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K to exclude such reconciliations, as the reconciliations of these non-U.S. GAAP guidance metrics to their corresponding U.S. GAAP equivalents are not available without

unreasonable effort.

Financial Results for Quarter Ended September 30, 2026:

•

Total net revenue was $356 million for the quarter ended September 30, 2026 (the 2026 quarter),

compared to $314 million for the quarter ended September 30, 2025 (the 2025 quarter), representing a 13% increase year-over-year.

•

Total SUBLOCADE net revenue was $267 million for the 2026 quarter, compared to $219 million for the

2025 quarter, representing a 22% increase year-over-year.

•

GAAP operating expenses were $125 million for the 2026 quarter, compared to $187 million for

the 2025 quarter, representing a 33% decrease year-over-year. Non-GAAP operating expenses, which exclude stock-based compensation expense and other adjustments, were $103 million for the 2026

quarter, compared to $145 million for the 2025 quarter, representing a 29% decrease year-over-year.

•

GAAP net income for the 2026 quarter was $137 million ($1.12 diluted earnings per share), compared

to GAAP net income for the 2025 quarter of $42 million ($0.33 diluted earnings per share). Non-GAAP net income for the 2026 quarter was $161 million ($1.32 diluted earnings per

share), compared to non-GAAP net income for the 2025 quarter of $93 million ($0.72 diluted earnings per share).

•

Adjusted EBITDA for the 2026 quarter was $211 million, compared to $120 million for the 2025

quarter, representing a 76% increase year-over-year.

•

The Company ended the 2026 quarter with cash and investments of $332 million.

Financial Results for Nine Months Ended September 30, 2026:

•

Total net revenue was $1,016 million for the nine months ended September 30, 2026 (the 2026 period),

compared to $881 million for the nine months ended September 30, 2025 (the 2025 period), representing a 15% increase year-over-year.

•

Total SUBLOCADE net revenue was $753 million for the 2026 period, compared to $604 million for the 2025

period, representing a 25% increase year-over-year.

•

GAAP operating expenses were $398 million for the 2026 period, compared to $521 million for

the 2025 period, representing a 24% decrease year-over-year. Non-GAAP operating expenses, which exclude stock-based compensation expense and other adjustments, were $331 million for the 2026 period,

compared to $459 million for the 2025 period, representing a 28% decrease year-over-year.

•

GAAP net income for the 2026 period was $348 million ($2.78 diluted earnings per share), compared

to GAAP net income for the 2025 period of $108 million ($0.85 diluted earnings per share). Non-GAAP net income for the 2026 period was $427 million ($3.41 diluted earnings per

share), compared to non-GAAP net income for the 2025 period of $213 million ($1.68 diluted earnings per share).

•

Adjusted EBITDA for the 2026 period was $562 million, compared to $286 million for the 2025

period, representing a 97% increase year-over-year.

About Indivior

As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and

advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence

and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living

with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.

Columns and rows within financial tables may not foot due to rounding. Percentages and per share data in the

financial tables have been calculated using actual, non-rounded figures.

Non-GAAP Financial Measures:

Non-GAAP financial measures adjust for non-recurring items and other items

representing expenses or income that we believe do not reflect the Company’s ongoing operations or the adjustment of which may help with the comparison to prior periods. The Company believes its non-GAAP

financial measures may be useful to investors to understand the Company’s performance. In addition, the Company uses “Adjusted EBITDA” in its annual incentive plan in which all executive officers participate.

Important Cautionary Note Regarding Forward-Looking Statements:

This announcement contains certain statements that are forward-looking statements. All statements other than statements of historical fact are forward-looking

statements. Forward-looking statements include, among other things, express and implied statements regarding: our 2026 financial guidance including with respect to net revenue, total SUBLOCADE net revenue,

non-GAAP operating expenses, and adjusted EBITDA; the expected completion and timing of the closing of our previously announced merger with Supernus, including the payment and timing of the special cash

dividend, the expected operation, performance, and prospects of the combined company; potential expense reductions; expected acceleration in SUBLOCADE net revenue and dispense unit growth; expected growth in adjusted EBITDA, cash flow, and our

bottom line, and expected acceleration of such growth; expected creation of shareholder value; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,”

“estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,”

“will,” “should,” “would,” “could,” “can,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties

as they relate to events or circumstances that may or may not occur in the future.

Prospective investors are cautioned that any such forward-looking

statements are not guarantees of future performance and only express management’s beliefs regarding future results or events which, by their nature, are inherently uncertain and outside of management’s control or ability to predict.

Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors, including but not limited to: market disruptions or unanticipated delays; lower than expected future sales of our

products; greater than expected impacts from competition; and unanticipated costs including the effects of potential tariffs and potential retaliatory tariffs; the effect of additional indebtedness incurred to fund the special cash dividend;

potential business disruption and diversion of management attention; difficulties integrating the businesses; and potential failure to realize anticipated benefits and synergies. For additional information about some of the risks and important

factors that could affect our future results and financial condition, see “Important Cautionary Note Regarding Forward-looking Statements” and “Risk Factors” in Indivior’s Annual Report on Form 10-K filed February 26, 2026, Indivior’s quarterly reports on Form 10-Q for the quarters ended March 31, June 30, and September 30, 2026, the

definitive joint proxy statement/prospectus filed September 11, 2026, and our other filings with the U.S. Securities and Exchange Commission.

have based the forward-looking statements in this release on our current expectations and beliefs concerning future events. Forward-looking statements contained in this release speak only as of the day they are made and, except as required by law,

we undertake no obligation to update or revise any forward-looking statement, whether due to new information, or to reflect events or developments that occur after the date the statement was made.

Important Additional Information and Where to Find It

connection with the proposed merger, Indivior filed a registration statement on Form S-4 with the SEC, which was declared effective on September 11, 2026 and includes a definitive joint proxy

statement/prospectus. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY BEFORE MAKING ANY VOTING OR INVESTMENT DECISION.

Free copies of these documents and other documents filed by Indivior with the SEC may be obtained at the SEC’s website at www.sec.gov. Copies of Indivior’s filings may also be obtained free of charge on Indivior’s website at

www.indivior.com, and copies of Supernus’s filings may be obtained free of charge on Supernus’s website at www.supernus.com.

No Offer or Solicitation

This announcement is not a solicitation of a proxy, consent or authorization in respect of any securities or in respect of the proposed merger, and it is not

an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the

securities laws of such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

For Further Information:

Investors

Jason Thompson

VP, Investor Relations

+1 804 402 7123

jason.thompson@indivior.com

Media

Cassie France-Kelly

VP, Communications

+1 804 594 0836

Indiviormediacontacts@indivior.com

Indivior Pharmaceuticals, Inc.

(Amounts in millions, except per share data and percentages)

(Unaudited)

Condensed consolidated

statements of operations

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Net revenue

356

314

1,016

881

Cost of sales

140

179

Gross profit

305

230

875

702

Selling, general and administrative

119

154

364

445

Research and development

Total operating expenses

125

187

398

521

Operating income

180

477

181

Interest (income)

)

(16

)

Interest expense

Loss on debt extinguishment

—

Income before income taxes

182

457

158

Income tax expense (benefit)

)

109

Net income

137

348

108

Earnings per share

Basic

1.16

0.34

2.89

0.87

Diluted

1.12

0.33

2.78

0.85

Indivior Pharmaceuticals, Inc.

(Amounts in millions, except per share data and percentages)

(Unaudited)

Condensed consolidated

balance sheets

September 30, 2026

December 31, 2025

Assets

Current assets

Cash and cash equivalents

305

195

Accounts receivable, net of allowances of $3 (2026) and $4 (2025)

273

253

Inventories

149

153

Prepaid expenses

Current tax receivable

Other current assets

Total current assets

800

652

Long-term investments

Property, plant and equipment, net

175

144

Operating lease right of use assets, net

Goodwill and other intangible assets, net

Deferred tax assets

288

323

Other noncurrent assets

Total assets

1,332

1,201

Liabilities and stockholders’ deficit

Current liabilities

Accrued rebates and product returns

548

582

Accounts payable and accrued expenses

181

250

Accrued litigation settlement expenses, current

Current portion of long-term debt

488

Operating lease liabilities, current

Income taxes payable

Total current liabilities

1,301

914

Long-term debt, less current portion

—

290

Accrued litigation settlement expenses, noncurrent

Operating lease liabilities, noncurrent

Other noncurrent liabilities

Total liabilities

1,392

1,300

Stockholders’ deficit

Common stock, par value $0.001 per share (2026) and $0.50 per share (2025). Issued shares:

118 (2026) and 125 (2025)

—

Additional paid-in capital

163

112

Accumulated other comprehensive loss

(26

)

(30

)

Accumulated deficit

(197

)

(243

)

Total stockholders’ deficit

(60

)

(98

)

Total liabilities and stockholders’ deficit

1,332

1,201

Indivior Pharmaceuticals, Inc.

(Amounts in millions, except per share data and percentages)

(Unaudited)

Condensed consolidated

statements of cash flows

Nine Months Ended September 30,

2026

2025

Cash flows from operating activities:

Net income

348

108

Adjustments to reconcile net income to net cash from operating activities:

Depreciation and amortization

Amortization of

right-of-use assets

Stock-based compensation expense

Impairment of tangible and intangible assets

Loss on debt extinguishment

—

Unrealized loss on equity investments

—

Deferred income taxes

)

Impact from foreign exchange movements

)

Amortization of debt issuance costs

—

Other adjustments, net

—

Change in operating assets and liabilities

(135

)

Net cash provided by operating activities

317

194

Cash flows from investing activities:

Purchases of property and equipment

(41

)

(42

)

Purchases of in-process research and development and

intangible assets

—

)

Purchases of investments in debt securities

(12

)

(14

)

Sales and maturities of debt securities

Net cash used in investing activities

(41

)

(42

)

Cash flows from financing activities:

Proceeds from the issuance of common stock

—

Cash paid for repurchases of common stock

(302

)

(11

)

Proceeds from debt, net

489

—

Repayments of debt

(333

)

(12

)

Transaction costs related to debt refinancing

)

—

Settlement of equity awards

(21

)

Other

—

Net cash used in financing activities

(166

)

(25

)

Net increase in cash and cash equivalents

110

128

Exchange differences

—

)

Cash and cash equivalents at beginning of period

195

319

Cash and cash equivalents at end of period

305

445

Indivior Pharmaceuticals, Inc.

(Amounts in millions, except per share data and percentages)

(Unaudited)

Selected revenue

information

Three Months Ended

September 30,

Nine Months Ended

September 30,

2026

2025

2026

2025

US:

SUBLOCADE*

252

203

707

561

Sublingual & other

160

157

OPVEE1

—

PERSERIS2

Total U.S.

307

267

880

745

Rest of World

136

137

Net revenue

356

314

1,016

881

*Total SUBLOCADE net revenue

267

219

753

604

Discontinued sales and marketing support for OPVEE®

during Q3 2025.

Marketing and promotion activities for PERSERIS were discontinued in 2024.

Reconciliation of GAAP to non-GAAP financial information

Three Months Ended

September 30,

Nine Months Ended

September 30,

2026

2025

2026

2025

GAAP operating expenses

125

187

398

521

Stock-based compensation

Corporate initiative transition1

Litigation settlement expense

—

Less: Adjustments in operating expenses

Non-GAAP operating expenses

103

145

331

459

Includes severance, consulting, impairment, and costs related to planned facility closures.

Non-GAAP diluted earnings per share

Management believes that non-GAAP diluted earnings per share, which excludes the impact of certain non-recurring items and other adjustments, net of applicable tax effects, may provide useful information to shareholders regarding underlying trends in earnings per share. A reconciliation of GAAP net income to non-GAAP net income, as well as the weighted average shares used in computing non-GAAP diluted earnings per share, is included in the table below.

Three Months Ended

September 30,

Nine Months Ended

September 30,

2026

2025

2026

2025

GAAP net income

137

348

108

Adjustments in cost of sales1

Adjustments in operating expenses

Adjustments in interest expense

—

Loss on debt extinguishment

—

Adjustments in tax expenses

)

(24

)

(19

)

Non-GAAP net income

161

427

213

Shares used in computing diluted non-GAAP earnings per

122

129

125

127

Non-GAAP diluted earnings per share

1.32

0.72

3.41

1.68

Includes manufacturing transition and other costs

Indivior Pharmaceuticals, Inc.

(Amounts in millions, except per share data and percentages)

(Unaudited)

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income adjusted to exclude interest expense,

interest income, income tax expense or benefit, depreciation and amortization, stock-based compensation, and other adjustments reflecting changes in our business that do not represent ongoing operations. Adjusted EBITDA margin is Adjusted EBITDA

divided by Total net revenue. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.

Three Months Ended

September 30,

Nine Months Ended

September 30,

2026

2025

2026

2025

Net income

137

348

108

Interest (income)

)

(16

)

Interest expense

Income tax expense (benefit)

)

109

Depreciation and amortization

Stock-based compensation

Corporate initiative transition

Manufacturing transition

Discontinuation of OPVEE sales and marketing

—

Loss on debt extinguishment

—

Litigation settlement expense

—

Adjusted EBITDA

211

120

562

286

GRAPHIC

Filename: g169609g98n48.jpg · Sequence: 6

Binary file (6835 bytes)

Download g169609g98n48.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Document and Entity Information

Oct. 29, 2026

Cover [Abstract]

Amendment Flag

false

Entity Central Index Key

0001625297

Document Type

8-K

Document Period End Date

Oct. 29, 2026

Entity Registrant Name

INDIVIOR PHARMACEUTICALS, INC.

Entity Incorporation State Country Code

Entity File Number

001-37835

Entity Tax Identification Number

41-2520873

Entity Address, Address Line One

10710 Midlothian Turnpike

Entity Address, Address Line Two

Suite 125

Entity Address, City or Town

North Chesterfield

Entity Address, State or Province

Entity Address, Postal Zip Code

23235

City Area Code

804

Local Phone Number

379-1090

Written Communications

true

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

common stock, $0.001 par value per share

Trading Symbol

INDV

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration